News articles about DexCom (NASDAQ:DXCM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DexCom earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 46.1516998290694 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

A number of research analysts have commented on DXCM shares. BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Piper Jaffray Companies reiterated a “buy” rating and issued a $78.00 price objective on shares of DexCom in a research note on Wednesday, July 12th. BMO Capital Markets reiterated a “buy” rating and issued a $105.00 price objective on shares of DexCom in a research note on Thursday, July 13th. Cowen and Company reiterated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Friday, July 14th. Finally, Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $72.19.

DexCom (DXCM) opened at 44.98 on Friday. The stock’s market cap is $3.89 billion. The company has a 50-day moving average price of $60.25 and a 200 day moving average price of $69.73. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. During the same period last year, the firm posted ($0.24) EPS. The business’s revenue was up 24.3% compared to the same quarter last year. On average, equities research analysts predict that DexCom will post ($0.80) EPS for the current year.

In other news, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $71.18, for a total transaction of $230,907.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $69.47, for a total value of $100,731.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,023 shares of company stock valued at $1,625,018. Insiders own 1.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “DexCom (DXCM) Given Media Sentiment Score of 0.02” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/10/20/dexcom-dxcm-given-media-sentiment-score-of-0-02.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.